Skip to main content
SpringerLink
Log in

Post-transplant Malignancies

  • Chapter
  • First Online:
Transplantation of the Pancreas

  • 339 Accesses

Abstract

Posttransplant malignancy is one of the most feared and devastating complications of organ transplantation. Due to the effects of chronic immunosuppression on viral infection, DNA damage, and cell survival mechanisms, transplant recipients face a dramatically elevated risk of some cancers. While many of these can be treated effectively at an early stage, knowledge of the risk factors is essential in the management of the pancreas transplant recipient. In this chapter, we examine the incidence and review the etiology of the major posttransplant solid tumors, and discuss some of the more recent developments in cancer therapeutics, which may have important implications for graft survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.

    Article  PubMed  Google Scholar 

  2. Greenberg JN, Zwald FO. Management of skin cancer in solid-organ transplant recipients: a multidisciplinary approach. Dermatol Clin. 2011;29(2):231–41.

    Article  CAS  PubMed  Google Scholar 

  3. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905–13.

    Article  PubMed  Google Scholar 

  4. Ramsay HM, Reece SM, Fryer AA, Smith AG, Harden PN. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation. 2007;84(3):437–9.

    Article  PubMed  Google Scholar 

  5. Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation. 2004;77(4):574–9.

    Article  CAS  PubMed  Google Scholar 

  6. Moloney FJ, Comber H, O’Lorcain P, O’Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol. 2006;154(3):498–504.

    Article  CAS  PubMed  Google Scholar 

  7. Chockalingam R, Downing C, Tyring SK. Cutaneous squamous cell carcinomas in organ transplant recipients. J Clin Med. 2015;4(6):1229–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ingo N, Marc G, Eggert S. Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers. 2007;23(4):247–59.

    Article  Google Scholar 

  9. Athar M, Walsh SB, Kopelovich L, Elmets CA. Pathogenesis of nonmelanoma skin cancers in organ transplant recipients. Arch Biochem Biophys. 2011;508(2):159–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wu X, Nguyen B-C, Dziunycz P, Chang S, Brooks Y, Lefort K, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature. 2010;465(7296):368–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Norman KG, Canter JA, Shi M, Milne GL, Morrow JD, Sligh JE. Cyclosporine A suppresses keratinocyte cell death through MPTP inhibition in a model for skin cancer in organ transplant recipients. Mitochondrion. 2010;10(2):94–101.

    Article  CAS  PubMed  Google Scholar 

  12. Hemmens VJ, Moore DE. Photochemical sensitization by azathioprine and its metabolites—I. 6-Mercaptopurine. Photochem Photobiol. 1986;43(3):247–55.

    Article  CAS  PubMed  Google Scholar 

  13. Cadet J, Douki T, Gasparutto D, Ravanat J-L. Oxidative damage to DNA: formation, measurement and biochemical features. Mutat Res Fundam Mol Mech Mutagen. 2003;531(1–2):5–23.

    Article  CAS  Google Scholar 

  14. O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu Y-Z, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309(5742):1871–4.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Vos M, Plasmeijer EI, van Bemmel BC, van der Bij W, Klaver NS, Erasmus ME, et al. Azathioprine to mycophenolate mofetil transition and risk of squamous cell carcinoma after lung transplantation. J Heart Lung Transplant. 2018;37(7):853–9.

    Article  PubMed  Google Scholar 

  16. Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet. 1997;349(9049):398.

    Article  CAS  PubMed  Google Scholar 

  17. Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer. 1991;67(8):2030–2.

    Article  CAS  PubMed  Google Scholar 

  18. Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016;4(1):70.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Lipson EJ, Bagnasco SM, Moore J, Jang S, Patel MJ, Zachary AA, et al. Tumor regression and allograft rejection after administration of anti–PD-1. N Engl J Med. 2016;374(9):896–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Krynitz B, Olsson H, Rozell BL, Lindelöf B, Edgren G, Smedby KE. Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study. Brit J Dermatol. 2016;174(1):95–103.

    Article  Google Scholar 

  21. Cusack CA, Nijhawan R, Miller B, Henien M, Malat G, Doyle A, et al. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient. JAMA Dermatol. 2015;151(1):70–2.

    Article  PubMed  Google Scholar 

  22. Woodle ES, Hanaway M, Buell J, Gross T, First MR, Trofe J, et al. Kaposi sarcoma: an analysis of the US and international experiences from the Israel Penn international transplant tumor registry. Transplantation. 2001;33(7–8):3660–1.

    CAS  Google Scholar 

  23. Regamey N, Tamm M, Wernli M, Witschi A, Thiel G, Cathomas G, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med. 1998;339(19):1358–63.

    Article  CAS  PubMed  Google Scholar 

  24. Frances C, Mouquet C, Marcelin AG, Barete S, Agher R, Charron D, et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation. 2000;69(9):1776–9.

    Article  CAS  PubMed  Google Scholar 

  25. Emond J-P, Marcelin A-G, Dorent R, Milliancourt C, Dupin N, Frances C, et al. Kaposi’s sarcoma associated with previous human herpesvirus 8 infection in heart transplant recipients. J Clin Microbiol. 2002;40(6):2217–9.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus; a successful treatment for posttransplantation Kaposi’s sarcoma12. Transplantation. 2004;77(5):760–2.

    Article  PubMed  Google Scholar 

  27. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA, et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell. 2006;10(2):133–43.

    Article  CAS  PubMed  Google Scholar 

  28. Vavricka BMP, Hofbauer GFL, Dummer R, French LE, Kempf W. Topical treatment of cutaneous Kaposi sarcoma with imiquimod 5% in renal-transplant recipients: a clinicopathological observation. Clin Exp Dermatol. 2012;37(6):620–5.

    Article  Google Scholar 

  29. Clarke CA, Robbins HA, Tatalovich Z, Lynch CF, Pawlish KS, Finch JL, et al. Risk of Merkel cell carcinoma after solid organ transplantation. JNCI. 2015;107(2):dju382.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus, and overall survival. Cancer Immun. 2013;1(1):54–63.

    Article  CAS  Google Scholar 

  33. Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. Br J Dermatol. 2006;154(3):472–7.

    Article  PubMed  Google Scholar 

  34. Engels EA, Pfeiffer RM, Fraumeni JF, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among us solid organ transplant recipients. JAMA. 2011;306(17):1891–901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation. 2002;74(10):1409–13.

    Article  PubMed  Google Scholar 

  36. Milton CA, Barbara J, Cooper J, Rao M, Russell C, Russ G. The transmission of donor-derived malignant melanoma to a renal allograft recipient. Clin Transpl. 2006;20(5):547–50.

    Article  CAS  Google Scholar 

  37. Liu Y, Sheikh MS. Melanoma: molecular pathogenesis and therapeutic management. Mol Cell Pharmacol. 2014;6(3):228.

    PubMed  PubMed Central  Google Scholar 

  38. Garrett GL, He SY, Sabouni N, Daud A, Arron ST. Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature. JAAD Case Rep. 2015;1(6):S23–5.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. Ann Oncol. 2016;27(6):1135–7.

    Article  CAS  PubMed  Google Scholar 

  40. Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit. Am J Transplant. 2010;10(8):1889–96.

    Article  CAS  PubMed  Google Scholar 

  42. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among canadian kidney transplant recipients. Am J Transplant. 2007;7(4):941–8.

    Article  CAS  PubMed  Google Scholar 

  43. Vajdic CM, McDonald SP, McCredie MRE, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–31.

    Article  CAS  PubMed  Google Scholar 

  44. Adamim J, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89:1221–27. https://doi.org/10.1038/sj.bjc.6601219.

  45. Hoshida Y, Tsukuma H, Yasunaga Y, Xu N, Fujita MQ, Satoh T, et al. Cancer risk after renal transplantation in Japan. Int J Cancer. 1997;71(4):517–20.

    Article  CAS  PubMed  Google Scholar 

  46. Corral JE, Croome KP, Keaveny AP, Brahmbhatt B, Kröner PT, Wijarnpreecha K, et al. A 3-decade analysis of pancreatic adenocarcinoma after solid organ transplant. Pancreas. 2021;50(1):54–63.

    Article  PubMed  Google Scholar 

  47. Penn I. Primary kidney tumors before and after renal transplantation. Transplantation. 1995;59(4):480–5.

    Article  CAS  PubMed  Google Scholar 

  48. Heinz-Peer G, Helbich T, Barnas U, Mayer G, Mühlbacher F, Mostbeck GH. Renal cell carcinomas of donor origin in two kidney transplants from a single donor. Transplantation. 1995;59(6):912–3.

    Article  CAS  PubMed  Google Scholar 

  49. McCarty TR, Njei B. Trends in malignant intraductal papillary mucinous neoplasm in US adults from 1990 to 2010: a SEER database analysis. Gastroenterol Rep. 2016;4(2):113–8.

    Article  Google Scholar 

  50. Lee JE, Choi S-Y, Min JH, Yi BH, Lee MH, Kim SS, et al. Determining malignant potential of intraductal papillary mucinous neoplasm of the pancreas: CT versus MRI by using revised 2017 international consensus guidelines. Radiology. 2019;293(1):134–43.

    Article  PubMed  Google Scholar 

  51. Roza AM, Johnson C, Juckett M, Eckels D, Adams M. Adenocarcinoma arising in a transplanted pancreas. Transplantation. 2001;72(6):1156–7.

    Article  CAS  PubMed  Google Scholar 

  52. Redmon JB, Teuscher AU, Robertson RP. Hypoglycemia after pancreas transplantation. Diabetes Care. 1998;21(11):1944–50.

    Article  CAS  PubMed  Google Scholar 

  53. Tran MP, Larsen JL, Duckworth WC, Ruby EI, Miller SA, Frisbie K, et al. Anti-insulin antibodies are a cause of hypoglycemia following pancreas transplantation. Diabetes Care. 1994;17(9):988–93.

    Article  CAS  PubMed  Google Scholar 

  54. Larsen J, Fellman S, Stratta R. Anti-insulin antibodies may cause hypoglycaemia following pancreas transplantation. Acta Diabetol. 1998;35(4):172–5.

    Article  CAS  PubMed  Google Scholar 

  55. Dombrowski F, Klingmüller D, Pfeifer U. Insulinomas derived from hyperplastic intra-hepatic islet transplants. Am J Pathol. 1998;152(4):1025–38.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Semakula C, Pambuccian S, Gruessner R, Kendall D, Pittenger G, Vinik A, et al. Hypoglycemia after pancreas transplantation: association with allograft nesidiodysplasia and expression of islet neogenesis-associated peptide. J Clin Endocrinol Metab. 2002;87(8):3548–54.

    Article  CAS  PubMed  Google Scholar 

  57. Filmer RB, Spencer JR. Malignancies in bladder augmentations and intestinal conduits. J Urol. 1990;143(4):671–8.

    Article  CAS  PubMed  Google Scholar 

  58. Meier RPH, Muller YD, Dietrich P-Y, Tille J-C, Nikolaev S, Sartori A, et al. Immunologic clearance of a BK virus-associated metastatic renal allograft carcinoma. Transplantation. 2021;105(2):423–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kaul DR, Vece G, Blumberg E, Hoz RML, Ison MG, Green M, et al. Ten years of donor-derived disease: a report of the disease transmission advisory committee. Am J Transplant. 2021;21(2):689–702.

    Article  PubMed  Google Scholar 

  60. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the united states in era of modern immunosuppression. Transplantation. 2005;80(9):1233–43.

    Article  CAS  PubMed  Google Scholar 

  61. Hall EC, Engels EA, Pfeiffer RM, Segev DL. Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation. 2015;99(5):1051–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Campistol JM, Cuervas-Mons V, Manito N, Almenar L, Arias M, Casafont F, et al. New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev. 2012;26(4):261–79.

    Article  Google Scholar 

  63. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351(9103):623–8.

    Article  CAS  PubMed  Google Scholar 

  64. Taylor AL, Watson CJE, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56(1):23–46.

    Article  PubMed  Google Scholar 

  65. Rutz HP, Herr I. Interference of glucocorticoids with apoptosis signaling and host-tumor interactions. Cancer Biol Ther. 2004;3(8):715–8.

    Article  CAS  PubMed  Google Scholar 

  66. Zhang C, Wenger T, Mattern J, Ilea S, Frey C, Gutwein P, et al. Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther. 2007;6(2):278–87.

    Article  CAS  PubMed  Google Scholar 

  67. Krisl JC, Doan VP. Chemotherapy and transplantation: the role of immunosuppression in malignancy and a review of antineoplastic agents in solid organ transplant recipients. Am J Transplant. 2017;17(8):1974–91.

    Article  CAS  PubMed  Google Scholar 

  68. Kourie HR, Klastersky JA. Side-effects of checkpoint inhibitor-based combination therapy. Curr Opin Oncol. 2016;28(4):306–13.

    Article  CAS  PubMed  Google Scholar 

  69. Mitchell KA, Kluger H, Sznol M, Hartman DJ. Ipilimumab-induced perforating Colitis. J Clin Gastroenterol. 2013;47(9):781–5.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther. 2013;13(6):847–61.

    Article  CAS  PubMed  Google Scholar 

  71. Belliere J, Meyer N, Mazieres J, Ollier S, Boulinguez S, Delas A, et al. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer. 2016;115(12):1457–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190–209.

    Article  CAS  PubMed  Google Scholar 

  73. Boils CL, Aljadir DN, Cantafio AW. Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy. Am J Transplant. 2016;16(8):2496–7.

    Article  CAS  PubMed  Google Scholar 

  74. Alhamad T, Venkatachalam K, Linette GP, Brennan DC. Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection. Am J Transplant. 2016;16(4):1332–3.

    Article  CAS  PubMed  Google Scholar 

  75. Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer. 2015;3(1):22.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Wentlandt K, Weiss A, O’Connor E, Kaya E. Palliative and end of life care in solid organ transplantation. Am J Transplant. 2017;17(12):3008–19.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, McGill University Health Centre, Montreal, Canada

    Steven Paraskevas

Authors
  1. Steven Paraskevas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Paraskevas .

Editor information

Editors and Affiliations

  1. Department of Surgery, State University of New York (SUNY), Downstate Health Sciences University, Brooklyn, NY, USA

    Rainer W. G. Gruessner

  2. Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, USA

    Angelika C. Gruessner

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Paraskevas, S. (2023). Post-transplant Malignancies. In: Gruessner, R.W.G., Gruessner, A.C. (eds) Transplantation of the Pancreas. Springer, Cham. https://doi.org/10.1007/978-3-031-20999-4_45

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-20999-4_45

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-20998-7

  • Online ISBN: 978-3-031-20999-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation